第六批高值医用耗材国家集采工作正式启动，头部国产企业有望凭借集采中选获得更多市场份额

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [1] Core Insights - The sixth batch of high-value medical consumables national centralized procurement has officially started, covering drug-coated balloon and urological intervention consumables, with a market scale exceeding 10 billion [4][9] - The procurement period is set until December 31, 2028, which will have a profound impact on the related industry chain and medical system [9] - Leading domestic companies are expected to gain more market share through successful procurement bids, despite short-term price declines impacting profit margins [6][14] Summary by Relevant Sections Industry Overview - The closing index is at 8269.04, with a 52-week high of 9323.49 and a low of 6764.34 [1] Recent Developments - The procurement document for drug-coated balloon and urological intervention consumables was released, marking the official start of the sixth batch of centralized procurement [4][9] - The procurement will include various high-value consumables, with specific annual demand quantities outlined for each type [10] Event Analysis - The procurement targets include drug-coated balloons for coronary arteries and peripheral blood vessels, as well as various urological intervention devices, with significant annual demand figures provided [10] - The highest effective bid prices will be determined based on provincial procurement prices and other pricing sources [11] Market Implications - The centralized procurement is expected to standardize the procurement and usage of medical consumables, improving industry ecology [14] - Companies with strong production cost reduction capabilities and good demand volumes are recommended for attention [6][14]